Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group has disclosed the 2025 audited financial results of its Shenzhen-listed subsidiary, Sinopharm Accord, highlighting its position in the Chinese pharmaceutical distribution and healthcare sector. The company reported modest asset and revenue scale, with net assets attributable to shareholders rising to RMB 18.61 billion at year-end 2025, underscoring a solid capital base.
For 2025, Sinopharm Accord’s revenue dipped 1.29% year on year to RMB 73.42 billion, but net profit attributable to shareholders surged 76.8% to RMB 1.14 billion, with an 88.53% jump in profit after excluding non-recurring items. Basic and diluted earnings per share rose to RMB 2.04 and weighted average ROE improved to 6.26%, though operating cash flow nearly halved, indicating stronger profitability but weaker cash generation during the period.
The most recent analyst rating on (HK:1099) stock is a Hold with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical and healthcare distributor with listed subsidiaries, including China National Accord Medicines Corporation Ltd. Sinopharm Accord’s A shares and B shares trade on the Shenzhen Stock Exchange, reflecting its role in China’s medicine distribution and related healthcare services market.
Average Trading Volume: 5,561,791
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$63.04B
See more data about 1099 stock on TipRanks’ Stock Analysis page.